Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging

Manabe, Osamu; Hattori, Naoya; Yamaguchi, Shigeru; Hirata, Kenji; Kobayashi, Kentaro; Terasaka, Shunsuke; Kobayashi, Hiroyuki; Motegi, Hiroaki; Shiga, Tohru; Magota, Keiichi; Oyama‐Manabe, Noriko; Nishijima, Ken‐ichi; Kuge, Yuji; Tamaki, Nagara

doi:10.1007/s00259-015-2996-7

Cited by 52 publications

(34 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies evaluating the DTA of MET PET to discriminate between LGG and HGG have shown inferior results when including oligodendroglial tumours. 41 While our study contradicts these results, the explanation can be our adherence to the WHO 2016 guidelines 1 by excluding oligoastrocytomas. Excluding oligoastrocytomas in the analysis yielded a similar AUC for the discrimination between LGG and HGG in astrocytomas and oligodendrogliomas respectively.…”

Section: Discussioncontrasting

confidence: 78%

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Delgado

2018

BJR

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 78%

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Delgado

2018

BJR

View full text Add to dashboard Cite

show abstract

“…24,27 Many researchers tried to address this issue using imaging markers derived from positron emission tomography, with conflicting results. [28][29][30] Interestingly, the difference between the pure astrocytoma and oligodendroglioma group was significant neither for grade II nor for grade III in this study. This might be due to the lack of robustness of iVASO or the relatively small sample in this cohort.…”

Section: Discussioncontrasting

confidence: 73%

“…It was reported that oligodendroglioma showed higher perfusion than pure astrocytoma, which might confound the reliability of perfusion metrics in predicting tumor grade and clinical outcomes . Many researchers tried to address this issue using imaging markers derived from positron emission tomography, with conflicting results . Interestingly, the difference between the pure astrocytoma and oligodendroglioma group was significant neither for grade II nor for grade III in this study.…”

Section: Discussioncontrasting

confidence: 57%

Association of Glioma Grading With Inflow‐Based Vascular‐Space‐Occupancy MRI: A Preliminary Study at 3T

Liao

Hua

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Inflow‐based vascular‐space‐occupancy (iVASO) MRI is a noninvasive perfusion technique that does not require administration of exogenous contrast agents. Arteriolar cerebral blood volume (CBVa) obtained from iVASO MRI is hypothesized to be an indicator of tumor microvasculature. Purpose To assess the diagnostic performance of iVASO MRI implemented at 3T in predicting histologic grades of cerebral gliomas. Study Type Retrospective. Subjects Forty‐five patients (31 males) consisting of 14 WHO grade IV glioblastoma multiformes, 14 grade III, and 17 grade II gliomas. Field Strength/Sequence At 3T we acquired CBVa data using an iVASO sequence. Assessment The maximum and mean CBVa (CBVa_max and CBVa_mean) values were calculated in the tumor and normalized to the contralateral thalamus (nCBVa_max and nCBVa_mean). Statistical Tests Kruskal–Wallis test, Mann–Whitney test, and receiver operating characteristics (ROC) curve were used for statistical analysis. Results Both CBVa_max and nCBVa_max increased with tumor grade (P < 0.001). Grade II gliomas showed CBVa_max <0.78 ml / 100 ml in 10/17 cases and nCBVa_max <1.20 in 11/17 cases. Grade III gliomas showed both CBVa_max >0.78 ml / 100 ml and nCBVa_max >1.20 in 13/14 cases, and CBVa_max <2.06 ml / 100 ml in 13/14 cases and nCBVa_max <2.33 in 11/14 cases. Grade IV gliomas showed CBVa_max >2.06 ml / 100 ml in 9/14 cases and nCBVa_max >2.33 in 13/14 cases. The areas under the ROC curve, sensitivity, and specificity were 0.839 (P < 0.001), 92.9% (26/28), and 64.7% (11/17) for CBVa_max, and 0.883 (P < 0.001), 92.9% (26/28), and 70.6% (12/17) for nCBVa_max in the discrimination between grade II and high‐grade (grade III and grade IV) tumors, respectively. Data Conclusion iVASO MRI might be used to help determine and predict glioma grade. Level of Evidence: 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1817–1823.

show abstract

“…18.11. It is well [45,46], and that MET is good at showing the tumor boundary. The FDG uptake increases with the tumor grade [47], and the results here suggest that FMISO uptake is absent in grades II and III, but strong in grade IV.…”

Section: Discussionmentioning

confidence: 91%

Hypoxia Imaging with 18F-FMISO PET for Brain Tumors

Hirata

Kobayashi

Tamaki

2016

Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy

Self Cite

View full text Add to dashboard Cite

Tumor hypoxia is an important object for imaging because hypoxia is associated with tumor aggressiveness and resistance to radiation therapy. Here, 18 Ffluoromisonidazole (FMISO) has been used for many years as the most commonly employed hypoxia imaging tracer. Unlike F-18 fluorodeoxyglucose (FDG), FMISO does not accumulate in normal brain tissue making it able to provide images of hypoxic brain tumors with high contrast. Clinical evidence has suggested that FMISO PET can predict patient prognosis and treatment response. Among gliomas of various grades (WHO 2007), it has been known that grade IV glioblastoma resides under severe hypoxia and is a cause of development of necrosis in the tumor. For this study we tested whether FMISO can distinguish the oxygen condition of glioblastomas and lower-grade gliomas. Twenty-three glioma patients underwent FMISO PET for the study. All the glioblastoma patients (N ¼ 14) showed high FMISO uptakes in the tumor, whereas none of the other patients (i.e., gliomas of grade III or lower, N ¼ 9) did, demonstrated by both qualitative and quantitative assessments. The data suggest that FMISO PET may be a useful tool to distinguish glioblastomas from lower-grade gliomas. Our results, however, were slightly different from previous investigations reporting that some lowergrade gliomas (e.g., grade III) showed positive FMISO uptake. Many of these acquired the FMISO PET images 2 h after the FMISO injection, while for the study here we waited 4 h to be able to collect hypoxia-specific signals rather than perfusion signals as FMISO clearance from plasma is slow due to its lipophilic nature. No optimum uptake time for FMISO has been established, and we directly compared the 2-h vs. the 4-h images with the same patients (N ¼ 17). At 2 h, the gray matter had significantly higher standardized uptake value (SUV) than the white matter, possibly due to different degrees of perfusion but not due to hypoxia. At 4 h, there were no differences between gray and white matter without any significant increase in the noise level measured by the coefficient of variation between the 2-h and the 4-h images. At 2 h, 6/8 (75 %) of glioblastoma patients showed higher uptakes in the tumor than in the surrounding brain tissue, whereas at 4 h this was the case for 8/8 (100 %). In addition, at 2 h, 3/4 (75 %) of patients with lower-grade gliomas showed moderate uptakes, while at 4 h none did (0/4 or 0 %). These data indicate that 4-h images are better than 2-h images for the purpose of glioma grading. In conclusion, we evaluated the diagnostic performance of FMISO PET for gliomas and suggest that FMISO PET may be able to assist in the diagnosis of glioblastomas when PET images are acquired at 4 h post injection.Keywords Hypoxia • 18 F-Fluoromisonidazole • Glioma • Glioblastoma IntroductionThis review article summarizes our recent studies with 18 F-fluoromisonidazole (FMISO) positron emission tomography (PET) applied to brain tumors [1,2]. A variety of tumors which can be divided into two categories develop ...

show abstract

Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging

Cited by 52 publications

References 20 publications

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Association of Glioma Grading With Inflow‐Based Vascular‐Space‐Occupancy MRI: A Preliminary Study at 3T

Hypoxia Imaging with 18F-FMISO PET for Brain Tumors

Contact Info

Product

Resources

About

Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging

Cited by 52 publications

References 20 publications

Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Association of Glioma Grading With Inflow‐Based Vascular‐Space‐Occupancy MRI: A Preliminary Study at 3T

Hypoxia Imaging with 18F-FMISO PET for Brain Tumors

Contact Info

Product

Resources

About

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis

Discrimination between primary low-grade and high-grade glioma with ¹¹C-methionine PET: a bivariate diagnostic test accuracy meta-analysis